4 References [1] M. M. Ohayon and A. F. Schatzberg, “Prevalence of depressive episodes with psychotic features in the general population,” American Journal of Psychiatry, vol. 159, no. 11, pp. 1855–1861, 2002. [2] A. J. Rothschild, D. J. Williamson, M. F. Tohen et al., “A double-blind, randomized study of olanzapine and olan- zapine/ﬂuoxetine combination for major depression with psychotic features,” Journal of Clinical Psychopharmacology, vol. 24, no. 4, pp. 365–373, 2004. [3] A. J. Rothschild, “Challenges in the treatment of depression with psychotic features,” Biological Psychiatry, vol. 53, no. 8, pp. 680–690, 2003. [4] J. A. Wheeler Vega, A. M. Mortimer, and P. J. Tyson, “Somatic treatment of psychotic depression: review and recommenda- tions for practice,” Journal of Clinical Psychopharmacology, vol. 20, no. 5, pp. 504–519, 2000. [5] A. F. Schatzberg and A. J. Rothschild, “Psychotic (delusional) major depression: should it be included as a distinct syndrome in DSM-IV?” American Journal of Psychiatry, vol. 149, no. 6, pp. 733–745, 1992. [6] A. F. Schatzberg, “New approaches to managing psychotic depression,” Journal of Clinical Psychiatry, vol. 64, no. 1, pp. 19–23, 2003. [7] American Psychiatric Association, “Practice guideline for the treatment of major depressive disorder (revision),” The American Journal of Psychiatry, vol. 157, supplement 4, pp. 1– 45, 2000. [8] D. G. Spiker, J. C. Weiss, R. S. Dealy et al., “The pharmacolog- ical treatment of delusional depression,” American Journal of Psychiatry, vol. 142, no. 4, pp. 430–436, 1985. [9] R. F. Anton and E. A. Burch, “Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression,” American Journal of Psychiatry, vol. 147, no. 9, pp. 1203–1208, 1990. [10] F. Ko¨nig, C. V. Hippel, T. Petersdorﬀ, M. Neuho¨ﬀer-Weiss, M. Wolfersdorf, and W. P. Kaschka, “First experiences in com- bination therapy using olanzapine with SSRIs ( Citalopram, Paroxetine) in delusional depression,” Neuropsychobiology, vol. 43, no. 3, pp. 170–174, 2001. [11] R. H. Weisler, E. P. Ahearn, J. R. T. Davidson, and C. D. Wallace, “Adjunctive use of olanzapine in mood disorders: ﬁve case reports,” Annals of Clinical Psychiatry, vol. 9, no. 4, pp. 259–262, 1997. [12] A. J. Rothschild, K. S. Bates, K. L. Boehringer, and A. Syed, “Olanzapine response in psychotic depression,” Journal of Clinical Psychiatry, vol. 60, no. 2, pp. 116–118, 1999. [13] W. Pitchot and M. Ansseau, “Addition of olanzapine for treatment-resistant depression,” American Journal of Psychia- try, vol. 158, no. 10, pp. 1737–1738, 2001. [14] S. Devarajan and S. M. Dursun, “Olanzapine plus venlafaxine in treatment-resistant depression,” Journal of Psychopharma- cology, vol. 19, no. 4, pp. 434–435, 2005. [15] E. C. Lauterbach, “Serotonin reuptake inhibitors, paranoia, and the ventral basal ganglia,” Clinical Neuropharmacology, vol. 14, no. 6, pp. 547–555, 1991. [16] A. P. Popli, M. A. Fuller, and G. E. Jaskiw, “Sertraline and psychotic symptoms: a case series,” Annals of Clinical Psychiatry, vol. 9, no. 1, pp. 15–17, 1997. [17] R. Zanardi, L. Franchini, A. Serretti, J. Perez, and E. Smeraldi, “Venlafaxine versus ﬂuvoxamine in the treatment of delu- sional depression: a pilot double-blind controlled study,” Journal of Clinical Psychiatry, vol. 61, no. 1, pp. 26–29, 2000. Case Reports in Medicine [18] A. R. Tyrka, L. H. Price, M. F. Mello, A. F. Mello, and L. L. Carpenter, “Psychotic major depression: a beneﬁt-risk assessment of treatment options,” Drug Safety, vol. 29, no. 6, pp. 491–508, 2006.